Chronic Kidney Disease (CKD) affects 10% of adults*, according to one of the most extensive real-world clinical practice studies conducted to date. This study reveals the significant burden that the disease imposes on patients and healthcare systems.

The study, carried out by experts from over 15 research centers in Europe and Canada, is one of the largest and most contemporary (2018-2021) investigations into CKD. It includes data from 2.4 million patients across 11 countries (in Europe, Canada, Israel). The study evaluates data obtained from digital healthcare systems to determine the prevalence of each stage of CKD, patient characteristics, risks, clinical outcomes, and associated costs.

CKD is one of the most common diseases, affecting 1 in every 10 people, as shown by the study. It also reveals that two out of three patients have not been diagnosed, putting these patients at a high risk of mortality.

CKD is a growing health burden with an increasing contribution to overall mortality, substantial financial costs, and an impact on healthcare professionals. The study finds that between 6-9% of CKD patients die every year. Additionally, CKD is the leading cause of hospitalizations and healthcare costs related to CKD and associated conditions such as heart failure (HF). The impact of CKD is expected to grow in the coming years, with the total number of cases and the costs of disease management increasing even further.

CKD is a serious, progressive condition affecting nearly 850 million people worldwide, associated with declining kidney function. The most common causes of its development are diabetes, hypertension, and glomerulonephritis. CKD is linked to significant patient morbidity and an increased risk of cardiovascular events, such as heart failure (HF), and premature death. In its most advanced and severe stage, CKD progresses to a point where dialysis or kidney transplantation becomes necessary.

*The average age of tracked individuals is 75 years, 53% are women, and 38% have diabetes. **Conducted among 2.4 million patients across 11 countries (in Europe, Canada, Israel).

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button